MiStent SES

**MiStent SES** is a coronary stent system designed for the treatment of coronary artery disease. It consists of a thin-strut cobalt chromium stent coated with a combination of crystalline sirolimus (an mTOR inhibitor for antiproliferative effect) and a biodegradable polymer (poly-lactide-co-glycolic acid, PLGA)[1][3][4]. The coating is rapidly absorbed (within 45–60 days), and the polymer is fully absorbed within 90 days, leaving the crystalline sirolimus in the tissue for up to 9 months, enabling sustained drug release. This controlled elution aims to reduce restenosis and minimize long-term polymer exposure safety concerns compared to conventional drug-eluting stents. Clinical studies show favorable efficacy and safety endpoints, including low rates of late lumen loss and major adverse cardiac events in patients with coronary artery disease[1][3][2]. The device is not approved in the United States but has CE Mark approval in Europe[1]. **Mechanism of action**: localized, sustained release of sirolimus (mTOR inhibition), suppresses smooth muscle cell proliferation, reducing neointimal hyperplasia and risk of restenosis.

Brand names

MiStent SES

Other names

MiStent Sirolimus-Eluting Absorbable Polymer Coronary Stent SystemMiStent